Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Peripheral blood plasma proteomics reveals dysregulated cholesterol transport and complement pathways in myeloproliferative neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

MPMax PetersenNANagib AhsanOOOmonike Oyelola

Discussion

Loading...

Member takes

Overview

Proteomic profiling reveals dysregulated cholesterol transport and complement pathways in myeloproliferative neoplasms, suggesting links to inflammatory responses.

Key Points

  • This research aims to explore proteomic alterations associated with myeloproliferative neoplasms and aging.
  • Liquid chromatography/mass spectrometry analysis of plasma from MPN patients and healthy donors.
  • Comparison of proteomic profiles between MPN patients and age-matched controls.
  • Identification of unique and common plasma proteins across sample groups.
  • Identified 1,224 unique plasma proteins from MPN patients and controls.
  • Marked differences in protein abundance between MPN patients and healthy controls discovered.
  • Significant dysregulation of cholesterol transport and complement activation pathways noted in MPN plasma samples.

Cite This Study

Petersen et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4b4https://doi.org/10.1182/blood-2025-3245
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Systemic Metabolic Changes in Plasma of Patients with Myelodysplastic Neoplasms and Chronic Myelomonocytic Leukemia2026
  2. 2Characterisation of the megakaryocyte proteome in patients with Philadelphia negative myeloproliferative neoplasms2025
  3. 3Integrated transcriptome-proteome analysis in patients with myelofibrosis-related anemia2026
  4. 4Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk2024 · 11 citations
  5. 5Molecular and Functional Platelet Abnormalities in Myeloproliferative Neoplasms2026